Maryland’s Prescription Drug Affordability Board is likely to set its first limits on drug companies in the next month.
The panel may put upper payment limits on two diabetes and heart failure medications after deeming the drugs were too expensive for Marylanders last July.
During a meeting next month, the board could put its first limits on Jardiance and Farxiga for state and local government plans, setting a firm boundary with drug companies on how much Maryland will pay for the drugs based on the maximum fair price.
